Lithium Carbonate
drugOn this page
Also known as Camcolit 250Camcolit 400Carbonic aciddilithium saltCP-1546761EskalithEskalith crLiskonumLithaneLithii carbonasLithium carbonicumLithobidLithonateLithotabsNSC-16895PhasalSID8139879
Summary
Lithium Carbonate (CHEMBL1200826) is an approved small-molecule antimanic drug; indicated across 43 conditions including depressive disorder and bipolar disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 43 conditions
- Clinical trials: 64
- Chemistry: 73.9 Da · CLi2O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200826 |
| Name | Lithium Carbonate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 11125 |
| ChEBI | CHEBI:6504 |
| Molecular formula | CLi2O3 |
| Molecular weight | 73.9 |
| InChIKey | XGZVUEUWXADBQD-UHFFFAOYSA-L |
SMILES: [Li+].[Li+].C(=O)([O-])[O-]
IUPAC name: dilithium;carbonate
Pharmacological roles (ChEBI): antimanic drug.
Also known as: Camcolit 250, Camcolit 400, Carbonic acid, dilithium salt, CP-1546761, Eskalith, Eskalith cr, Liskonum, Lithane, Lithii carbonas, Lithium carbonate, Lithium carbonicum
Patent coverage: 69,760 distinct patent families (152,377 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
43 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| depressive disorder | 4 | MONDO:0002050 | MONDO:0002050 |
| bipolar disorder | 4 | MONDO:0004985 | EFO:0009963 |
| stroke disorder | 3 | MONDO:0005098 | EFO:0000712 |
| conduct disorder | 3 | MONDO:0005352 | EFO:0004216 |
| anxiety | 3 | MONDO:0011918 | EFO:0005230 |
| dementia | 3 | MONDO:0001627 | HP:0000726 |
| autism spectrum disorder | 3 | MONDO:0005258 | EFO:0003756 |
| internal carotid artery stenosis | 3 | MONDO:0005189 | EFO:0002615 |
| neutropenia | 3 | MONDO:0001475 | MONDO:0001475 |
| amyotrophic lateral sclerosis | 3 | MONDO:0004976 | MONDO:0004976 |
| alcohol abuse | 3 | MONDO:0002046 | MONDO:0007079 |
| carotid artery disorder | 3 | MONDO:0005269 | EFO:0003781 |
| Machado-Joseph disease | 2 | MONDO:0007182 | Orphanet:98757 |
| multiple system atrophy | 2 | MONDO:0007803 | EFO:1001050 |
| bone fracture | 2 | MONDO:0005315 | EFO:0003931 |
| spinal cord injury | 2 | MONDO:0043797 | EFO:1001919 |
| neuroendocrine neoplasm | 2 | MONDO:0019496 | EFO:1001901 |
| brain cancer | 2 | MONDO:0001657 | MONDO:0001657 |
| differentiated thyroid carcinoma | 2 | MONDO:0015447 | EFO:1002017 |
| Alzheimer disease | 2 | MONDO:0004975 | MONDO:0004975 |
| Huntington disease | 2 | MONDO:0007739 | MONDO:0007739 |
| frontotemporal dementia | 2 | MONDO:0017276 | MONDO:0017276 |
| long COVID-19 | 2 | MONDO:0100233 | MONDO:0100233 |
| small cell lung carcinoma | 1 | MONDO:0008433 | EFO:0000702 |
| central nervous system neoplasm | 1 | MONDO:0006130 | EFO:1000158 |
| Parkinson disease | 1 | MONDO:0005180 | MONDO:0005180 |
| multiple sclerosis | 1 | MONDO:0005301 | MONDO:0005301 |
| progressive supranuclear palsy | 1 | MONDO:0019037 | MONDO:0019037 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| Niemann-Pick disease type C | 0 | MONDO:0018982 | MONDO:0018982 |
13 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 64.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 16 |
| PHASE4 | 15 |
| PHASE3 | 11 |
| PHASE1 | 8 |
| PHASE1/PHASE2 | 5 |
| Not specified | 5 |
| PHASE2/PHASE3 | 3 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06184581 | PHASE4 | RECRUITING | Lithium Versus Lamotrigine in Bipolar Disorder, Type II |
| NCT00177567 | PHASE4 | COMPLETED | Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study |
| NCT00202306 | PHASE4 | COMPLETED | Indicated Prevention of Psychotic Disorders With Low-dose Lithium |
| NCT00602537 | PHASE4 | COMPLETED | Antidepressant Therapy in Treating Bipolar Type II Major Depression |
| NCT00641927 | PHASE4 | COMPLETED | Antidepressant Therapy for Bipolar II Major Depression |
| NCT00667745 | PHASE4 | COMPLETED | Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder |
| NCT00870311 | PHASE4 | COMPLETED | Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients |
| NCT01669369 | PHASE4 | UNKNOWN | Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma |
| NCT02918097 | PHASE4 | COMPLETED | Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode |
| NCT03056248 | PHASE4 | UNKNOWN | Lithium in Acute Kidney Injury |
| NCT03148535 | PHASE4 | UNKNOWN | Guidance Model of Standardized Treatment of Antidepressants in Bipolar Disorder |
| NCT03185208 | PHASE4 | COMPLETED | Lithium As a Treatment to Prevent Impairment of Cognition in Elders |
| NCT04222816 | PHASE4 | COMPLETED | Effect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder |
| NCT04479566 | PHASE4 | COMPLETED | Effect of Lithium Carbonate on Postoperative Sleep in Patients Undergoing Videoassisted Thoracic Surgery |
| NCT04826510 | PHASE4 | UNKNOWN | Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Disorder Depression |
| NCT00000369 | PHASE3 | COMPLETED | Maintenance Therapies in Bipolar Disorders |
| NCT00057681 | PHASE3 | COMPLETED | Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents |
| NCT00276965 | PHASE3 | COMPLETED | Bipolar II Depression: Lithium, SSRI, or the Combination |
| NCT00485680 | PHASE3 | COMPLETED | Olanzapine Versus Comparator in the Treatment of Bipolar Disorder |
| NCT00789854 | PHASE3 | COMPLETED | Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients |
| NCT00818389 | PHASE2/PHASE3 | TERMINATED | Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS) |
| NCT00883493 | PHASE3 | COMPLETED | Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression |
| NCT01096082 | PHASE2/PHASE3 | COMPLETED | Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 |
| NCT01112813 | PHASE3 | COMPLETED | The Neurotrophic Effects of Lithium Carbonate Following Stroke: A Feasibility Study |
| NCT01166425 | PHASE2/PHASE3 | COMPLETED | Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania. |
| NCT04623398 | PHASE3 | COMPLETED | Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency) |
| NCT05126238 | PHASE3 | TERMINATED | A Lithium-Based Medication to Improve Neurological Outcomes After Surgical Carotid Reconstruction |
| NCT05221593 | PHASE3 | COMPLETED | Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients |
| NCT06008249 | PHASE3 | TERMINATED | Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS) |
| NCT05814640 | PHASE1/PHASE2 | RECRUITING | Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) |
| NCT07540338 | PHASE1/PHASE2 | RECRUITING | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder |
| NCT00114439 | PHASE2 | COMPLETED | Lithium Cannabis Withdrawal Study |
| NCT00240110 | PHASE1/PHASE2 | COMPLETED | Valproate Efficacy in Cocaine-Bipolar Comorbidity |
| NCT00251316 | PHASE2 | COMPLETED | Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer |
| NCT00442039 | PHASE2 | COMPLETED | Lithium for the Treatment of Pediatric Mania |
| NCT00501540 | PHASE2 | COMPLETED | Lithium for Low-Grade Neuroendocrine Tumors |
| NCT00582712 | PHASE2 | TERMINATED | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer |
| NCT00750061 | PHASE2 | COMPLETED | Efficacy and Safety of Lithium Carbonate in the Treatment of Chronic Spinal Cord Injuries |
| NCT00790582 | PHASE2 | COMPLETED | A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS) |
| NCT00997672 | PHASE2 | TERMINATED | Lithium in Multiple System Atrophy |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).